Biopharmaceutical
Seladelpar Treatment of PBC Patients for Two Years Predicts Improved Transplant-Free Survival Excerpt from the Press Release: NEWARK, Calif., June 22, 2022 (GLOBE NEWSWIRE) — CymaBay Therapeutics, Inc. (NASDAQ: CBAY), a clinical-stage biopharmaceutical company focused on developing therapies for liver and other chronic diseases with high unmet need, today announced encouraging seladelpar data in patients…
Read More
— Novel biomarker will be used to identify patients in genetically defined subgroup associated with poorer outcomes — Study will evaluate SYK inhibitor both in patients with wild-type disease and those with tumors that harbor MYD88 or CD79b mutations Excerpt from the Press Release: SOUTH SAN FRANCISCO, Calif., June 23, 2022 (GLOBE NEWSWIRE) — Calithera…
Read More
Excerpt from the Press Release: Results demonstrate novel synergistic effects of IL-12 and T cell receptor signaling in anti-tumor immunity PENNINGTON, N.J. and SAN DIEGO, June 24, 2022 /PRNewswire/ — OncoSec Medical Incorporated (NASDAQ: ONCS) (the “Company” or “OncoSec”), a clinical-stage biotechnology company focused on developing intratumoral immunotherapies to stimulate the patient’s own immune system to target…
Read More
Excerpt from the Press Release: SUNNYVALE, Calif., June 15, 2022 (GLOBE NEWSWIRE) — BioCardia®, Inc. [Nasdaq: BCDA], a developer of cellular and cell-derived therapeutics for the treatment of cardiovascular and pulmonary diseases, today announces that the United States Patent Office has granted Patent Number 11,357,463: titled, “Target Site Selection, Entry and Update With Automatic Remote Image…
Read More Excerpt from the Press Release: FREMONT, CA, June 16, 2022 (GLOBE NEWSWIRE) — via NewMediaWire – ABVC Biopharma, Inc. (NASDAQ: ABVC), a clinical stage biopharmaceutical company developing therapeutic solutions in oncology/hematology, CNS, and ophthalmology, today announced the submission of its Vitrargus Phase II study to the Australian Bellberry Human Research Ethics Committee (HREC). If received,…
Read More
Pre-Clinical Research Could Lead to Rapid Development of Dopamine-Producing Neurons; Part of Company’s NIH-Funded Program Seeking Scalable Cell Replacement Therapy Approaches for Parkinson’s Disease Use of Non-Viral, Self-Amplifying RNA Enhanced and Lengthened Transcription Factor Expression, Driving the Signaling Required for Dopamine-Producing Neuron Development Findings Presented at 2022 International Society for Stem Cell Research Annual Meeting…
Read More
Excerpt from the Press Release: SAN DIEGO–(BUSINESS WIRE)–Lassen Therapeutics, a biotech company developing breakthrough antibody therapeutics as potential treatments for fibrosis, rare diseases and oncology, today presented new preclinical data on LASN01, a monoclonal antibody targeting IL-11 receptor (IL-11R), in preclinical models of skin fibrosis at the Keystone Symposia Conference on Tissue Fibrosis and Repair:…
Read More
− 177Lutetium-labelled radiohybrid Prostate-Specific Membrane Antigen (177Lu-rhPSMA-10.1) is in development as a highly optimized, next generation therapeutic radiopharmaceutical – − 177Lu‑rhPSMA-10.1 demonstrated favorable tumor:kidney ratio and statistically significant tumor growth suppression in preclinical studies − − Phase 1/2 clinical trial of 177Lu-rhPSMA-10.1 in men with metastatic castrate‑resistant prostate cancer recently cleared to proceed in United…
Read More
– Study evaluates pre-administration of cold antibody prior to administration of imaging agent – Imaging shows favorable gain in tumor lesion uptake versus normal tissue when cold antibody is pre-administered – Data presented at the SNMMI 2022 Annual Meeting Excerpt from the Press Release: HAMILTON, ON and BOSTON, June 14, 2022 /PRNewswire/ — Fusion Pharmaceuticals Inc.…
Read More
KT-333 is a first-in-class heterobifunctional degrader of the transcriptional regulator STAT3 in development for T cell malignancies and solid tumors KT-413 is a first-in-class degrader of IRAK4 and the IMiD substrates Ikaros and Aiolos in development for MYD88-mutant B cell lymphomas Initial safety and proof-of-mechanism clinical data for both programs to be shared in second…
Read More